ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1686 • ACR Convergence 2021

    Efficacy and Safety of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by TNF-α Inhibitor Therapy

    Eugen Feist1, Saeed Fatenejad2, Sergey Grishin3, Elena Korneva3, Michael Luggen4, Evgeniy Nasonov5, Mikhail Samsonov6 and Roy Fleischmann7, 1Helios Department of Rheumatology, Vogelsang-Gommern, Germany, 2SFC Medica, LLC, Charlotte, NC, 3R-Pharm, Moscow, Russia, 4Cincinnati Rheumatic Disease Study Group, Inc., and University Hospital/University of Cincinnati College of Medicine, Cincinnati, OH, 5V.A. Nasonova Reseach Institute of Rheumatology, Moscow, Russia, 6RPharm, Moscow, Russia, 7Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: Olokizumab (OKZ), a humanized monoclonal antibody targeting IL-6, was studied in patients with active Rheumatoid Arthritis (RA) despite methotrexate (MTX) (NCT02760368, NCT02760407) [1]. Here…
  • Abstract Number: 1708 • ACR Convergence 2021

    The Efficacy and Safety of Piclidenoson vs Methotrexate in Early Rheumatoid Arthritis: Phase 3 Randomized, Double-blind, Placebo-controlled Study

    Tatiana Reitblat1, Alexandra Gurman- Balbir2, Zivit Harpaz3, Motti Farbstein3, Michael Silverman3, William Kerns3 and Pnina Fishman3, 1Barzilai Medical Center, Ashkelon, Israel, 2Rambam Medical Center, Haifa, Israel, 3Can-Fite BioPharma, Petah Tikva, Israel

    Background/Purpose: Piclidenoson, a highly selective A3 adenosine receptor (A3AR) agonist, demonstrated safety and efficacy in phase 2 clinical studies in rheumatoid arthritis (RA) and psoriasis.…
  • Abstract Number: 1737 • ACR Convergence 2021

    Reduction in Urinary CD163 Is Associated with Treatment Response in the Belimumab Lupus Nephritis Trial

    Emma Weeding1, Andrea Fava2, Chandra Mohan3, Daniel Goldman4 and Michelle Petri4, 1Johns Hopkins Hospital, Baltimore, MD, 2Johns Hopkins University, Baltimore, MD, 3University of Houston, Houston, TX, 4Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Urinary CD163 is a macrophage marker which correlates with histological activity index and response to treatment in lupus nephritis (LN), as evidenced by urine…
  • Abstract Number: 1717 • ACR Convergence 2021

    One Year After the Publication of the American College of Rheumatology (ACR) Guidelines for Management of Reproductive Health in Rheumatic Diseases, Has Anything Changed? An Analysis of Rheumatology Practice at a Tertiary Care Medical Center

    Yixuan Zhou1 and Sobia Hassan2, 1Rush University Medical Center, Chicago, IL, 2RUSH University, Chicago, IL

    Background/Purpose: Successful pregnancies in patients with rheumatic disease are possible when they are well-monitored, adequately treated, and planned during periods of disease quiescence. Previously, a…
  • Abstract Number: 1732 • ACR Convergence 2021

    Effects of B Cell Activating Factors/B Lymphocyte Stimulator Inhibitors Added to Standard of Care on Infection in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    Ruoning Ni1, Jiayi Zheng2 and Ruru Guo3, 1Saint Agnes Healthcare, Baltimore, MD, 2Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (People's Republic), 3Renji Hospital, Shanghai, China (People's Republic)

    Background/Purpose: The efficacy of B cell activator factor/B lymphocyte stimulator inhibitors (BAFFi/BLySi) for systemic lupus erythematosus (SLE) has been proven in clinical trials. However, it…
  • Abstract Number: 1744 • ACR Convergence 2021

    Improvement of Renal and Non-Renal SLE Outcome Measures on Sirolimus Therapy – a 21-year Follow-up Study of 73 Patients

    Paramarajan Piranavan1 and Andras Perl2, 1SUNY Upstate Medical University, Syracuse, NY, 2State University of New York, Syracuse, NY

    Background/Purpose: The clinical heterogeneity of the SLE makes it often challenging for the treating clinician and also remains one of the many reasons behind failed…
  • Abstract Number: 1739 • ACR Convergence 2021

    SLE Treatment History and Anifrolumab Efficacy by Baseline Standard Therapies in Patients with SLE from 2 Phase 3 Trials

    Susan Manzi1, Richard Furie2, Eric Morand3, Yoshiya Tanaka4, Gabriel Abreu5, Catharina Lindholm5 and Raj Tummala6, 1Allegheny Health Network, Pittsurgh, PA, 2Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, 3Monash University, Melbourne, Australia, 4University of Occupational and Environmental Health, Kitakyushu, Japan, 5BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 6BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD

    Background/Purpose: In the phase 3 TULIP-1 and TULIP-2 trials, anifrolumab, a type I IFN receptor mAb, improved disease activity versus placebo in patients with moderate…
  • Abstract Number: 1736 • ACR Convergence 2021

    Treatment of Lupus Nephritis with Belimumab Is Associated with Reduction in Urinary CD23

    Emma Weeding1, Andrea Fava2, Chandra Mohan3, Daniel Goldman4 and Michelle Petri4, 1Johns Hopkins Hospital, Baltimore, MD, 2Johns Hopkins University, Baltimore, MD, 3University of Houston, Houston, TX, 4Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Urine proteomic approaches have shown promise in identifying dynamic biological pathways in lupus nephritis (LN) which are not captured on renal histopathology or by…
  • Abstract Number: 1729 • ACR Convergence 2021

    Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus (SLE) Using 2nd Trimester Estimated Glomerular Filtration Rate (eGFR)

    Anika Lucas1, Amanda Eudy1, Michelle Petri2, Rebecca Fischer-Betz3, Abeer Nabil4, Cecilia Nalli5, Laura Andreoli6, Angela Tincani7, Yair Molad8, Stephen Balevic1 and Megan Clowse9, 1Duke University, Durham, NC, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3Uniklinik Dsseldorf, Dsseldorf, Germany, 4University of Cairo, Cairo, Egypt, 5ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, 6University of Brescia, Brescia, Italy, 7ASST Spedali Civili-University of Brescia, Gussago, Italy, 8Rabin Medical Center, Beilinson Hospital, and Tel Aviv University, Petah-Tikva, Israel, 9Duke University, Chapel Hill, NC

    Background/Purpose: Women with SLE are at increased risk for adverse maternal and fetal outcomes with increased odds of preeclampsia, hypertension, Cesarean and preterm deliveries, low…
  • Abstract Number: 1742 • ACR Convergence 2021

    Efficacy of Anifrolumab in Serological Subgroups of Patients with SLE Participating in 2 Phase 3 Trials

    Ian N. Bruce1, Ronald Van Vollenhoven2, Yoshiya Tanaka3, Eric Morand4, Richard Furie5, Konstantina Psachoulia6, Emmanuelle Maho7, Catharina Lindholm8, Christi Kleoudis9 and Raj Tummala6, 1University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, 2Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, 3University of Occupational and Environmental Health, Kitakyushu, Japan, 4Monash University, Melbourne, Australia, 5Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, 6BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 7BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, 8BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 9BioPharmaceuticals R&D, AstraZeneca, Durham, NC

    Background/Purpose: In the TULIP-2 and TULIP-1 trials of patients with SLE, the type I IFN receptor mAb anifrolumab resulted in higher BILAG–based Composite Lupus Assessment…
  • Abstract Number: 1733 • ACR Convergence 2021

    Classification of Patients with Systemic Lupus Erythematosus Enrolled in 2 Phase 3 Trials by EULAR/ACR 2019 Criteria

    Martin Aringer1, Ian N. Bruce2, Richard Furie3, Eric Morand4, Emmanuelle Maho5, Catharina Lindholm6 and Raj Tummala7, 1University Medical Center and Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, 2University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, 3Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, 4Monash University, Melbourne, Australia, 5BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, 6BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 7BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD

    Background/Purpose: The TULIP-1 and TULIP-2 trials of anifrolumab, an anti–type I IFN receptor mAb, enrolled autoantibody-positive (ANA, anti-dsDNA, and/or anti-Smith [anti-Sm]) patients, who fulfilled the…
  • Abstract Number: 1699 • ACR Convergence 2021

    The “ITIS” Diet Improves Fatigue in Patients with Rheumatoid Arthritis and Is Associated with Changes in Metabolome and Fecal Microbiome

    Roxana Coras1, Cameron Martino1, Julia Gauglitz1, Alan Jarmusch1, Anupriya Tripathi1, Francesca Cedola2, Marta Fernandez-Bustamante1, Meritxall Agustín-Perez1, Maram Alharthi1, Susan Lee1, Abha Singh1, Soo In Choi1, Tania Rivera1, Katherine Nguyen3, Tatyana Shekhtman1, Tiffany Holt1, Shahrokh Golshan1, Rob Knight1, Pieter C Dorrestein1 and Monica Guma1, 1University of California San Diego, La Jolla, CA, 2University of California San Diego, Rome, CA, Italy, 3University of California San Diego, San Diego, CA

    Background/Purpose: Fatigue is common symptom in rheumatoid arthritis (RA), associated with decreased quality of life and productivity. Fatigue mechanisms have not been well studied, hence,…
  • Abstract Number: 1638 • ACR Convergence 2021

    Clinical Manifestations of COVID-19 and Its Impact on Pediatric Patients with Rheumatic Disease

    Belina Yi, Sindhu Mohandas and Michal Cidon, Children's Hospital Los Angeles, Los Angeles, CA

    Background/Purpose: Spread of SARS-COV-2 during the COVID-19 pandemic has raised concerns for patients with rheumatic disease. Rheumatology patients have an increased risk of developing infectious…
  • Abstract Number: 1641 • ACR Convergence 2021

    Long-term Cardiovascular Disease and Mortality Following Kawasaki Disease in Childhood: A Systematic Review

    Francis Lao1, Cal Robinson2, Megan Schlorff1, Jocelyne Ewusie3, Karen Beattie1 and Michelle Batthish1, 1McMaster University, Hamilton, ON, Canada, 2The Hospital for Sick Children, Hamilton, ON, Canada, 3St Joseph's Healthcare, Hamilton, ON, Canada

    Background/Purpose: Kawasaki Disease (KD) is a common vasculitis of childhood, with an annual North American incidence of 20-26 per 100,000 children (< 5 years of…
  • Abstract Number: 1654 • ACR Convergence 2021

    Comparative Characteristics of the Natural Course of Early Rheumatoid Arthritis with Onset at a Young Age (18-49 Years) and Older (50 Years and Older) Patients Who Did Not Take DMARDs, Biologics, Other Targeted Drugs, Corticoids According to the Russian Register of Arthritis OREL

    Azamat Satybaldyev, Galina Gridneva, Anna Misiyuk, Natalia Demidova, Kamalia Kasumova and Evgeny Nasonov, V.A. Nasonova Reseach Institute of Rheumatology, Moscow, Russia

    Background/Purpose: Comparison of frequency of different clinical features of the natural course at the stage of early rheumatoid arthritis (RA) in patients with young and…
  • « Previous Page
  • 1
  • …
  • 547
  • 548
  • 549
  • 550
  • 551
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology